Such an IL-4 variant could be of great interest to treat certain organ-specific autoimmune diseases, such as rheumatoid arthritis and psoriasis, by precisely controlling timing and location of activation without inducing systemic adverse side effects. The gene discussed is IL4; the disease is psoriasis.